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Hypoglycemia is associated with serious health outcomes for patients treated for 
diabetes mellitus. However, the outcome of outpatients with type 2 diabetes who have 
experienced hypoglycemia episodes is largely unknown. 
Research Design and Methods 
The study population, derived from the National Health Insurance Research 
Database released by the Taiwan National Health Research Institutes during 
1998–2009, comprised 77,611 newly diagnosed patients with type 2 diabetes mellitus. 
We designed a prospective study consisting of randomly selected, hypoglycemic type 
2 diabetes patients and matched type 2 diabetes patients without hypoglycemia. We 
investigated the relationships of hypoglycemia with total mortality and cardiovascular 
events including stroke, coronary heart disease, cardiovascular diseases (CVD), and 
all-cause hospitalization. 
Results 
There were 1,844 hypoglycemic events (500 inpatients and 1,344 outpatients) 
among the 77,611 patients. Both mild (outpatient) and severe (inpatient) 
hypoglycemia cases had a higher percentage of comorbidities, including hypertension, 
renal diseases, cancer, stroke, and heart disease. In multivariate Cox regression 
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models, including diabetes treatment adjustment, diabetes patients with hypoglycemia 
had a significantly higher risk of cardiovascular events during clinical treatment 
periods. After constructing a model adjusted with propensity scores, mild and severe 
hypoglycemia still demonstrated higher hazard ratios for CVD (2.09; 95% confidence 
interval 1.63–2.67), all-cause hospitalization (2.51, 2.00–3.16), and total mortality 
(2.48; 1.41–4.38).  
Conclusions 
 Symptomatic hypoglycemia, whether clinically mild or severe, is associated with 
an increased risk of cardiovascular events, all-cause hospitalization, and all-cause 













 Hypoglycemia is a major side effect of glucose-lowering therapy in both type 1 
and type 2 diabetes mellitus patients. Patients with type 2 diabetes are believed to 
usually have less-frequent hypoglycemia episodes than type 1 patients (1). Prodromal 
symptoms of hypoglycemia, including tremor, diaphoresis, tachycardia, and anxiety, 
are sometimes noticed by the patient, and consequently severe complications can be 
avoided. If left untreated, however, neuroglycopenia may develop, resulting in 
neurological damage (2, 3). 
Hypoglycemia has also been associated with adverse cardiovascular events in 
type 2 diabetes patients beyond hypoglycemic episodes themselves (4). The surge of 
sympathetic activity during hypoglycemic episodes has been suggested to be the 
underlying mechanism, leading to destabilization of atherosclerotic plaques (5), 
increased arrhythmia owing to increased corrected QT interval (6), and induction of 
cardiac and cerebral ischemia. Studies including epidemiological cohort studies and 
clinical trials (7, 8, 9, 10) have already suggested that hypoglycemia is indeed a risk 
factor for cardiovascular outcomes. However, some patients in these studies had 
comorbidities on admission, such as unstable angina and acute myocardial infarction 
(11, 12, 13, 14). Recently, the ADVANCE study suggested that hypoglycemia is 
associated with increased risks of a range of adverse clinical outcomes and is 
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considered to be a marker for vulnerability to such events for type 2 diabetes patients 
(15).  
Whether hypoglycemia is a risk factor or a marker, it is important to evaluate the 
possible correlates to both hypoglycemia and serious health conditions, including 
hepatic disease, malignancy, renal disease, and use of various medications. 
Furthermore, in real-world clinical practice it is intriguing to identify hypoglycemic 
events based solely on symptoms or a physician’s diagnosis rather than on glucose 
levels, as most previous studies have done. Moreover, patient selection bias, 
especially the Berkson’s bias, in hospital-based observational or case-control studies 
probably confounds and casts doubt on the associations between hypoglycemia and 
clinical outcomes. Lastly, the clinical impact of mild, self-reported hypoglycemic 
episodes is largely unknown. We therefore conducted this nationwide, random 
sampling, cohort study of type 2 diabetes patients to characterize their comorbidities, 




RESEARCH DESIGN AND METHODS 
Study population 
In Taiwan, National Health Insurance is a single-payer program that has operated 
since 1995, covering 98% of the population. The database includes patient 
demographics, diagnosis, and prescriptions in the hospital and in outpatient claims. 
Currently, the National Health Research Institutes (NHRI) is in charge of the National 
Health Insurance Research Database (NHIRD) in Miaoli, Taiwan (available at: 
www.nhri.org.tw/nhird/), and the complete National Health Insurance claims database 
along with several dozen extracted datasets are available to researchers. A nationally 
representative group of one million individuals was randomly selected from all 
insured persons in NHIRD, which is also one of the largest nationwide 
population-based databases in the world. All selected insured persons’ medical 
records from 1996 to 2009 were included in the dataset. For research purposes, the 
information on all persons was managed with a double scrambling protocol. The 
original identification number was encrypted to protect privacy while maintaining 
consistency. Therefore, it was possible to follow patients by linking claims belonging 
to the same patient within the NHIRD datasets. Since the National Health Insurance 
was initiated from 1996, the claim data was not totally comepleted. We included data 





 We designed a cohort of type 2 diabetes patients from the one million patients in 
the nationally representative sample dataset. We excluded patients with diabetes 
medical records before December 31, 1997. A total of 77,611 new diabetes patients 
were identified as having received a diagnosis of diabetes more than three times 
[ICD-9CM: 250.XXX] from 1998 to 2009. Among them, 500 diabetes patients with 
hypoglycemia [ICD-9-CM: 251.2X] were identified from the hospital claims dataset 
(defined as severe hypoglycemia), and 1,344 diabetes patients with hypoglycemia 
were identified from the outpatient claims dataset (defined as mild hypoglycemia).  
Further, we also designed a cohort consisting of hypoglycemic type 2 diabetes 
patients and randomly selected and matched them with type 2 diabetes patients 
without hypoglycemia. To control for the confounding effects of age, gender, and 
diabetes duration, we constructed a matched variable containing the age at 
hypoglycemia onset, gender, and diabetes duration for each patient with 
hypoglycemia. The diabetes duration was calculated from the first diagnosis date to 
the date of hypoglycemia onset. 
Then we used SAS MACRO to identify hypoglycemic diabetes patients with the 
same matched variable and randomly selected one to four non-hypoglycemic diabetes 
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cases from those with the same match variables. Finally, we randomly selected 7,376 
diabetes patients without hypoglycemia by matching age of hypoglycemia onset, 
gender, and diabetes duration. Each matched pair had the same initial date 
(hypoglycemia onset date) signaling the commencement of follow-up (Figure 1). 
Definition of variables 
Patients with a diagnosis of diabetes were defined as those with three outpatient 
claims with ICD-9-CM code 250. All confounding variables were defined according 
to the diagnosis before the index date in hypoglycemic and non-hypoglycemic 
patients. Hypertension was defined as two outpatient claims with ICD-9-CM code 
401–405. Dyslipidemia was defined as two outpatient claims with ICD-9-CM code 
272. Atrial fibrillation was defined as two outpatient claims with ICD-9-CM 427.3X. 
Liver cirrhosis was defined as two outpatient visits with ICD-9-CM between 571.2X 
or 571.5X. Renal disease was defined as two outpatient visits with ICD-9-CM 
between 580 and 589. Mental diseases were defined as two outpatient visits with 
ICD-9-CM between 290 and 319. The socioeconomic status was defined according to 
the insured’s salary (median: 16,500 new Taiwan dollars). Compliance with diabetes 
treatment was measured by proportion of days covered of treatment (PDC) (16). 
Sufficient compliance of treatment for diabetes was defined PDC ≥ 80% (17). 
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Cancer, stroke, coronary heart disease (CHD), and cardiovascular disease (CVD) 
were also identified from the hospital claim dataset. Cancer diseases were defined by 
ICD-9-CM codes between 140 and 239. Stroke was defined by ICD-9CM codes 
430–438. CVD was defined by ICD-9-CM codes 390–459. 
Death status was ascertained according to (1) the discharge reasons with death or 
critically ill discharge, or (2) quit insurance with death. 
Statistical methods 
 The different groups were compared using the unpaired Student’s t-test for 
parametric continuous data and the chi-square test for categorical data. We 
investigated the relationship between hypoglycemia and cardiovascular events. 
Survival time was calculated from the date of hypoglycemia diagnosis for each data 
pair to the onset date of the event (stroke, CHD, CVD, or any cause for 
hospitalization), death, or end of study (December 31, 2009). The Kaplan-Meier 
method was used to estimate the survival curves, and the log-rank test was used to test 
the homogeneity between survival curves. Hazard ratio (HR) and the 95% confidence 
interval (CI) for the Cox proportional hazard model were used to evaluate the 
association between hypoglycemia and cardiovascular events. We also performed a 
propensity score analysis to evaluate the association between hypoglycemia and 
cardiovascular events, hospitalization, and total mortality. All statistical analyses were 
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Incidence of hypoglycemia  
There were 1,844 hypoglycemic events (500 in inpatients and 1,344 in 
outpatients) among 77,611 new type 2 diabetes patients from 1998–2009. The 
incidence of hypoglycemia was 2.38% (1,844/77,611). Women had a higher risk of 
hypoglycemia than men (1.34% vs. 1.04%, p < 0.0001).  
 
Characteristics of hypoglycemic and matched non-hypoglycemic type 2 diabetes 
patients (Table 1) 
Hypertension, atrial fibrillation, liver cirrhosis, renal disease, mental disease, 
history of cancer disease, stroke, and heart disease were positively associated with 
hypoglycemia risk. The percentage of insulin and sulfonylureas usage and good 
compliance with diabetes medications were also higher in both mild and severe 
hypoglycemia cases. However, social economic status did not differ significantly 
between hypoglycemic and non-hypoglycemic cases. Owing to the matched 
conditions, the variables age, gender, and duration of diabetes did not differ between 
hypoglycemic and non-hypoglycemic patients (Table 1). In both mild and severe 
hypoglycemia matched case controls, comorbidities independently associated with 
hypoglycemia were: hypertension (HR = 1.75; 95% CI: 1.57–1.96), atrial fibrillation 
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(1.96; 1.24–3.11), liver cirrhosis (1.71; 1.17–2.48), renal disease (3.26; 2.76–3.86), 
mental disease (1.50; 1.30–1.73), cancer (2.73; 2.12–3.50), stroke (2.84; 2.31–3.48), 
and coronary heart disease (2.04; 1.65–2.51). 
 
Total mortality and incidence of stroke, CHD, and cardiovascular events in 
hypoglycemic diabetes patients 
 During the follow-up period, 1,187 diabetes patients developed stroke, 1,164 
developed CHD, 3,515 developed cardiovascular events, and 773 died before the end 
of the study. 
Patients with hypoglycemia had a significantly higher risk of cardiovascular 
events during the clinical treatment periods (Figure 2). Compared with patients 
without hypoglycemia, those with hypoglycemia (both inpatient and outpatient claims 
datasets) had a higher hospitalization rate for stroke (27.97 vs. 69.05, 71.73 
respectively, per 1000 person-years; both p < 0.0001), CHD (27.96 vs.65.51, 65.77 
respectively, per 1000 person-years, both p < 0.0001), CVD hospitalization (106.00  
vs.323.36, 325.79 respectively, per 1000 person-years, both p < 0.0001), and total 
mortality (14.30 vs.41.04, 52.28 respectively, per 1000 person-years, all comparisons, 
p < 0.0001). Both inpatients and outpatients with hypoglycemia carried a more than 
2-fold higher relative risk of stroke (HR = 2.55; 95% CI = 2.24–2.90), CHD events 
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(2.35; 2.06–2.68), CVD (3.19; 2.94–3.47), and total mortality (3.49; 3.01–4.05). 
Table 2 shows the independent risk factors for stroke events, CHD events, 
cardiovascular events, and total mortality. In the multivariate Cox regression model, 
both mild and severe hypoglycemia events showed increased HRs for stroke, CHD, 
and all cardiovascular events after adjusting for other important co-morbidities. 
Furthermore, we also estimated the association between hypoglycemia and 
cardiovascular events, hospitalization, and total mortality for patients with insulin 
treatment (n = 1,068) and sulphonylurea treatment (n = 4,817). The HRs (95% CI) for 
mild and severe hypoglycemia were as follows: 2.57 (0.73–9.09) and 1.44 (0.40–5.17), 
respectively, for stroke; 2.06 (0.76–5.57) and 2.10 (0.45–9.77), respectively, for CHD; 
2.21 (1.39–3.53) and 1.48 (0.69–3.19), respectively, for CVD; and 1.94 (0.79–4.76) 
and 2.67 (0.68–10.45), respectively, for total mortality for patients with insulin 
treatment. Hypoglycemia was significantly and positively correlated with 
cardiovascular events and mortality for patients receiving sulphonylurea treatment. 
The HRs for mild and severe hypoglycemia were as follows: 1.82 (1.41–2.34) and 
1.32 (0.96–1.82), respectively, for stroke; 1.88 (1.47–2.42) and 1.35 (0.99–1.85), 
respectively, for CHD; 2.32 (1.98–2.70) and 1.96 (1.59–2.43), respectively, for CVD; 
and 2.97 (2.22–3.97) and 2.24 (1.53–3.27), respectively, for total mortality. As shown 
in Table 2, the results were similar for patients who had good medication compliance, 
15 
 
as defined by PDC. 
 
Hypoglycemia and hospitalization 
The hospitalization rate was 73.1% (1,348/1,844) among hypoglycemic diabetes 
patients during the observation period. Hypoglycemic patients had a 3.54-fold higher 
risk of being hospitalized (CI = 3.27–3.82). Further, the first-year hospitalized rate 
was 53.1% (714/1344) for patients with mild hypoglycemia and 63.4% (317/500) for 
those with severe hypoglycemia (Figure 2B). Moreover, 76.5% (n = 1,031/1,384) of 
hospitalization events occurred during the first year after hypoglycemia onset. The 
reason for admission of these hypoglycemic patients in the first year included CVD 
(ICD: 390–459, 22.0%), diabetes (ICD-9-CM: 250, 18.5%), genitourinary disease 
(ICD-9-CM: 580–629, 10.7%), and digestive disease (ICD-9-CM: 520–527, 8.7%).  
Propensity score analysis 
 Propensity score analysis was conducted to evaluate the association between 
hypoglycemia, including both mild and severe cases, and hospitalization for 
cardiovascular events and total mortality. The distributions of potential confounding 
variables (Supplemental Table S1) did not differ significantly between diabetes 
mellitus patients with or without hypoglycemia in the propensity score matched data. 
Hypoglycemic patients had about a 2-fold higher relative risk of cardiovascular events 
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(HR = 2.09; 95% CI = 1.63–2.67), hospitalization (2.51; 2.00–3.16), and total death 







The major findings of this study suggest that hypoglycemia episodes, both mild and 
severe, are strongly associated with subsequent major cardiovascular events including 
stroke, CHD, and CVD hospitalization in outpatient-treated type 2 diabetes patients. 
Furthermore, higher all-cause mortality was associated with these hypoglycemic 
events. Diabetes patients who are vulnerable to hypoglycemia have more 
comorbidities including hypertension, liver cirrhosis, renal disease, mental disease, 
cancer, and previous stroke or heart diseases. Medications, including insulin and 
sulfonylurea, are also important factors that impact clinical events related to 
hypoglycemia. Once outpatient-treated diabetes patients have hypoglycemic episodes, 
cardiovascular and hospitalization events occur most frequently in the first year after 
the hypoglycemic event regardless of whether the hypoglycemia was mild or severe.  
 The incidence of clinical hypoglycemic events, including both mild and severe 
types, was lower in our study than in previous clinical trials such as ACCORD
 
(12) 
and community epidemiological studies in other countries such as the United 
Kingdom
 
(19, 20). A lower proportion of patients with hypoglycemia has been 
reported in Asian Pacific countries and Taiwan (18), which may be explained by more 
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conservative treatment strategies in Taiwanese clinical diabetes control (21). 
 In recent years, intensive glucose control strategies for long-duration type 2 
diabetes patients have been intensively studied, including in the VADT (13), 
ADVANCE (14), and ACCORD trials (12). These trials did not consistently support 
strategies to improve reductions in cardiovascular events or mortality. Excessive 
mortality in intensive glucose control groups has led to debate regarding 
hypoglycemia-related adverse outcomes. However, a post-hoc analysis of the data 
from the ACCORD trial suggests that the excess mortality in the intensively treated 
group cannot be directly explained by the more frequent episodes of hypoglycemia in 
this group of patients (22). The post-hoc analysis of the data from the ADVANCE 
study also recently suggests that severe hypoglycemia is strongly associated with 
increased risk of adverse clinical outcomes, including macrovascular and 
microvascular changes and death from cardiovascular events. Because there is no 
relationship between repeated hypoglycemia episodes and adverse outcomes, the 
authors conclude that hypoglycemia is a likely marker of vulnerability to such events 
(15). 
 Although some previous studies have shown that hypoglycemia is a risk factor 
for future cardiovascular events, these analyses were almost all based on patients 
recruited during hospitalization (7, 8). Most of the epidemiological analyses were 
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from clinical trials related to acute myocardial infarction, including the DIGAMI-2 
and OASIS-6 trials (9, 10).
 
In contrast, our study population was recruited from 
real-world outpatient clinical practice, and our results suggest that clinically driven 
hypoglycemia in diabetes may increase adverse cardiovascular outcomes and 
hospitalization from any cause by about 2-fold. Even after propensity score–adjusted 
analysis, hypoglycemia still carries about 2.0–2.5 times the risk for CVD events, 
all-cause hospitalization, and all-cause mortality. Our result was similar to a 
retrospective epidemiological analysis of the ACCORD study, which showed an HR 
of ~2.87 for all-cause mortality with severe versus no severe episodes of 
hypoglycemia in a standard treatment group (22). These observations suggest that 
hypoglycemia occurs as a consequence of intensive therapeutic intervention and has a 
different relationship with serious cardiovascular outcomes or death than spontaneous 
hypoglycemia or episodes that occur as part of routine diabetes management (4). 
 Furthermore, many previous studies have suggested that hypoglycemia is a risk 
factor for serious health outcomes. Combined with evidence that therapies promoting 
hypoglycemia do not increase these outcomes, hypoglycemia is more likely to be 
associated with other risk factors for these outcomes rather than causally related to 
them (22). On the other hand, studies have demonstrated that hypoglycemia events in 
general-ward patients have a dose-dependent relationship with the length of hospital 
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stay and in-hospital mortality (23). Hypoglycemia may result in poor outcomes for 
diabetes patients by leading to falls, seizures, or non-medical death. This was not 
found in our study, as the most frequent causes of hospitalization were for CVD, 
diabetes, genitourinary disease, and digestive disease. Our results also suggest that 
hypoglycemia may be a marker for disease severity in these routinely treated diabetes 
patients. Diabetes patients who experienced hypoglycemic episodes were more likely 
to be on insulin and sulphonylurea and have better treatment compliance. This may 
indirectly indicate a greater severity of diabetes for patients prone to hypoglycemic 
events. However, data for blood sugar or HbA1c levels are not present in this type of 
administration database, and so these parameters could not be considered.  
 Some papers have studied the possible mechanics of symptomatic hypoglycemia 
and suggested that hypoglycemia may predispose patients to adverse cardiovascular 
outcomes. Hypoglycemia may be associated with elevated sympathetic activity and 
release of catecholamines, thereby promoting destabilization of atherosclerotic 
plaques (24). Hemodynamic changes with increased myocardial work, 
hypoglycemia-induced increase in platelet aggregation, and platelet activity may also 
precipitate cardiac or cerebral ischemic insults in high-risk type 2 diabetes patients 
(25, 26).
 
Additionally, one study revealed a higher frequency of ischemic 
electrocardiogram changes or a nocturnal increase in the corrected QT interval 
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accompanied by rhythm disturbance when hypoglycemia develops (27). 
 In this nationwide cohort study, we also found that diabetes patients who are 
prone to hypoglycemia episodes are more likely to have comorbidities such as 
hypertension, renal disease, heart disease, stroke, and cancer history with borderline 
atrial fibrillation and liver disease. Previous studies also support this association of 
severe hypoglycemia with older age, longer duration of diabetes, higher creatinine 
level, use of two or more oral glucose-lowering agents, and assignment to intensive 
glucose control (28). Although our study patients were matched for age, gender, and 
diabetes duration, this trend of associations was still evident.  
Limitations 
 First, neither the educational status of individuals nor information about personal 
habits such as smoking, extent of physical activity, body mass index, or the exact 
condition of glycemic control were available from the NHIRD. Second, this study was 
conducted with data from NHIRD, and the diagnosis was assumed to have been 
confirmed clinically by the individual physician in charge. The occurrence of mild or 
severe hypoglycemia was only confirmed by the outpatient or inpatient record of 
clinical hypoglycemia, and patient glucose levels were not recorded. By using a 
case-control study design, we hoped to minimize the impact of selection, 
misclassification, and diagnostic bias. Third, the study population consisted of 
22 
 
Taiwanese patients who were of Chinese descent, and thus, the results may not be 
easily generalized to other populations. 
 In conclusion, symptomatic hypoglycemia, both clinically mild and severe, is 
associated with an increased risk for cardiovascular events, all-cause hospitalization, 
and all-cause mortality. Adverse events after hypoglycemia occurred most frequently 
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Table 1 Characteristics of diabetes patients with hypoglycemia and matched diabetes patients without hypoglycemia 
 Severe 
hypoglycemia 
(n = 500) 
 No 
hypoglycemia 
(n = 2,000) 
p-value  Mild 
hypoglycemia 
(n = 1,344) 
 No 
hypoglycemia 
(n = 5,376) 
p-value 
Age, years 65.2 ± 9.2  65.2 ± 9.2 1.0000  62.6 ± 9.6  62.6 ± 9.6 1.0000 
Males  233 46.60%  932 46.60% 1.0000  573 42.63%  2292 42.63% 1.0000 
Duration, yrs 3.75 ± 2.8  3.75 ± 2.8 1.0000  5.41 ± 3.1  5.41 ± 3.1 1.0000 
Hypertension  318 63.60%  1023 51.15% <0.0001  895 66.59%  2600 48.36% <0.0001 
Atrial fibrillation  6 1.20%  14 0.70% 0.2616  27 2.01%  45 0.84% 0.0002 
Dyslipidemia  85 17.00%  433 21.65% 0.0218  408 30.36%  1351 25.13% <0.0001 
Liver cirrhosis  15 3.00%  26 1.30% 0.0074  32 2.38%  78 1.45% 0.0162 
Renal disease  87 17.40%  103 5.15% <0.0001  226 16.82%  286 5.32% <0.0001 
Mental disease  107 21.40%  250 12.50% <0.0001  262 19.49%  688 12.80% <0.0001 
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Cancer  40 8.00%  48 2.40% <0.0001  84 6.25%  130 2.42% <0.0001 
Stroke  75 15.00%  80 4.00% <0.0001  150 11.16%  176 3.27% <0.0001 
Heart disease 66 13.20%  72 3.60% <0.0001  132 9.82%  203 3.78% <0.0001 
High social economic status  214 42.80%  937 46.85% 0.1041  700 52.08%  2854 53.09% 0.5094 
Good compliance 142 28.40%  529 26.45% 0.3788  302 22.47%  866 16.11% <0.0001 
Insulin 121 24.20%  87 4.35% <0.0001  460 34.23%  400 7.44% <0.0001 
Sulfonylureas 339 67.80%  1099 54.95% <0.0001  912 67.86%  2467 45.89% <0.0001 
Other drugs 307 61.40%  940 47.00% <0.0001  894 66.52%  2404 44.72% <0.0001 
Other drugs: Other orally administered diabetes medications.  
Good compliance of treatment: Proportion of days covered (PDC) > 80%. 
High social economic status: salary of the insured more than the median (16,500 new Taiwan dollars).  
Data shown are mean ± standard deviation or number of patients and percent. 
31 
 
Table 2. Association between hypoglycemia and hospitalization due to stroke, coronary heart disease, and cardiovascular causes in the multivariate model.  
  Stroke CHD CVD Death 
Variables HR 95% CIs HR 95% CIs HR 95% CIs HR 95% CIs 
Hypertension, Yes vs. No 1.61  1.39–1.86 1.53  1.31–1.78  1.95  1.78–2.13 1.28  1.07–1.54  
Atrial fibrillation, Yes vs. No 1.26  0.63–2.52 1.49  0.79–2.82  1.67  1.12–2.48 0.93  0.43–2.01  
Dyslipidemia, Yes vs. No 0.88  0.75–1.05 1.33  1.12–1.57  1.01  0.91–1.11 0.73  0.59–0.91  
Liver cirrhosis, Yes vs. No. 0.60  0.31–1.16 0.60  0.30–1.19  1.49  1.09–2.05 2.28  1.32–3.93  
Renal disease, Yes vs. No 1.26  0.97–1.63 1.49  1.17–1.91  1.79  1.54–2.08 2.01  1.52–2.65 
Mental disease, Yes vs. No 1.12  0.93–1.35 1.04  0.86–1.26  1.03  0.92–1.16 1.12  0.83–1.43  
Previous cancer, Yes vs. No 0.66  0.43–1.01 0.58  0.36–0.92  1.03  0.81–1.31 2.03  1.36–3.02 
Previous stroke, Yes vs. No 4.26  3.35–5.42 0.76  0.56–1.03  1.42  1.19–1.69 1.26  0.91–1.74 
Heart disease, Yes vs. No 1.13  0.85–1.52 4.73  3.68–6.08  1.96  1.64–2.34 1.30  0.94–1.79 
High social economic status  0.94  0.81–1.09 0.91  0.78–1.05  0.96  0.87–1.04 0.58  0.48–0.71 
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Good compliance 1.15  0.97–1.36 1.06  0.90–1.25  1.14  1.03–1.26 1.21  0.98–1.49 
Insulin 1.63  1.29–2.07 1.54  1.21–1.95  1.74  1.51–2.01 1.74  1.34–2.27 
Sulfonylureas 1.17  1.00–1.37 1.30  1.11–1.53  1.34  1.22–1.47 1.38  1.14–1.67 
Mild hypoglycemia 1.92  1.60–2.31 1.76  1.46–2.13  2.21  1.98–2.47 2.70  2.19–3.33 
Severe hypoglycemia 1.64  1.29–2.07 1.63  1.28–2.08  2.26  1.93–2.65 2.18  1.66–2.88 
Other drugs: Other oral diabetes medications.  
Good compliance of treatment: Proportion of days covered (PDC) > 80%. 





Figure 1. Flow chart of study population  
 
Figure 2. Association between hypoglycemia and hospitalization. (A) Survival curves for patients with 
hypoglycemia and hospitalization. (B) The hospitalization rate (n = 1,348) during the follow-up period was 
53.1% (n = 714/1,344) for mild hypoglycemia and 63.4% (n = 317/500) for severe and occurred in the first 
year.    
Figure 1. Flow chart of study population 
77,611 diabetic patients treated for diabetes 
≥3 times [ICD-9-CM: 250.XX]) from the one 
million insured individuals who were newly 
diagnosed during 1998-2009 
500 DM with 
hypoglycemia [ICD-9-CM: 
251.2] were identified 
from the hospital claims 
data set 
 
1,344 DM with 
hypoglycemia [ICD-9-CM: 
251.2] were identified 
from the outpatient 
claims data set 
Age, gender, and duration 
of DM were matched 
between 2,000 DM 
without hypoglycemia 
and 500 DM with 
hypoglycemia 
 
Age, gender, and duration 
of DM were matched 
between 5,376 DM 
without hypoglycemia 
and 1,344 DM with 
hypoglycemia 
Stroke, coronary heart 
disease, cardiovascular 



























Figure 2. Association between hypoglycemia and hospitalization. (A) Survival curves of hypoglycemia 
and hospitalization. (B) The hospitalized rates (n=1348) during the follow-up period, was 53.1% 
(714/1344) for mild and 63.4% (n=317/500) for severe occurred in the first year, respectively.    
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